Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects

Podjanee Jittamala, Sasithon Pukrittayakamee, Elizabeth A Ashley, François Nosten, Borimas Hanboonkunupakarn, Sue J Lee, Praiya Thana, Kalayanee Chairat, Daniel Blessborn, Salwaluk Panapipat, Nicholas J White, Nicholas P J Day, Joel Tarning, Podjanee Jittamala, Sasithon Pukrittayakamee, Elizabeth A Ashley, François Nosten, Borimas Hanboonkunupakarn, Sue J Lee, Praiya Thana, Kalayanee Chairat, Daniel Blessborn, Salwaluk Panapipat, Nicholas J White, Nicholas P J Day, Joel Tarning

Abstract

Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine. A single-dose, randomized, three-sequence crossover study was conducted in healthy Thai volunteers to characterize potential pharmacokinetic interactions between these drugs. Seventeen healthy adults received a single oral dose of primaquine alone (30 mg base) and were then randomized to receive pyronaridine-artesunate alone (540-180 mg) or pyronaridine-artesunate plus primaquine in combination, with intervening washout periods between all treatments. The pharmacokinetic properties of primaquine, its metabolite carboxyprimaquine, artesunate, its metabolite dihydroartemisinin, and pyronaridine were assessed in 15 subjects using a noncompartmental approach followed by a bioequivalence evaluation. All drugs were well tolerated. The single oral dose of primaquine did not result in any clinically relevant pharmacokinetic alterations to pyronaridine, artesunate, or dihydroartemisinin exposures. There were significantly higher primaquine maximum plasma drug concentrations (geometric mean ratio, 30%; 90% confidence interval [CI], 17% to 46%) and total exposures (15%; 6.4% to 24%) during coadministration with pyronaridine-artesunate than when primaquine was given alone. Pyronaridine, like chloroquine and piperaquine, increases plasma primaquine concentrations. (This study has been registered at ClinicalTrials.gov under registration no. NCT01552330.).

Copyright © 2015, Jittamala et al.

Figures

FIG 1
FIG 1
Observed mean (±SD) concentration-time profiles for primaquine (A), carboxyprimaquine (B), artesunate (C), dihydroartemisinin (D) and pyronaridine (E). Solid lines indicate when drugs are administered alone and dashed lines indicate when drugs are administered as a combination. The inset in panel E shows the concentration-time profile of pyronaridine during the first day. The drug-sampling matrix was plasma for artesunate, dihydroartemisinin, primaquine, and carboxyprimaquine and whole blood for pyronaridine.
FIG 2
FIG 2
Forest plots of the geometric mean ratios (±90% confidence intervals [CI]) of the drug administered with and without interacting drugs for logarithmically transformed Cmax, AUC0–last, and AUC0–∞. The vertical dashed lines represent the US FDA criteria of 80 to 125% for assuming bioequivalence.

References

    1. World Health Organization. 2012. World malaria report 2012. World Health Organization; Geneva, Switzerland: .
    1. Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin CS, Fleckenstein L. 2013. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J 12:70. doi:10.1186/1475-2875-12-70.
    1. World Health Organization. 2010. Global report on antimalarial efficacy and drug resistance: 2000-2010. World Health Organization; Geneva, Switzerland: .
    1. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization; Geneva, Switzerland: .
    1. Galappaththy GNL, Tharyan P, Kirubakaran R. 2013. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 10:CD004389. doi:10.1002/14651858.CD004389.pub3.
    1. Graves PM, Gelband H, Garner P. 2012. Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 9:CD008152. doi:10.1002/14651858.CD008152.pub3.
    1. Baird JK, Hoffman SL. 2004. Primaquine therapy for malaria. Clin Infect Dis 39:1336–1345. doi:10.1086/424663.
    1. World Health Organization. 2012. Malaria Policy Advisory Committee Meeting. WHO Evidence Review Group: the safety and effectiveness of single dose primaquine as a P. falciparum gametocytocide. World Health Organization; Geneva, Switzerland. .
    1. Edwards G, McGrath CS, Ward SA, Suparananond W, Pukrittayakamee S, Davis TM, White NJ. 1993. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol 35:193–198. doi:10.1111/j.1365-2125.1993.tb05685.x.
    1. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rickman KH, Edstein MD. 2006. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol 61:682–689. doi:10.1111/j.1365-2125.2006.02601.x.
    1. Elmes NJ, Bennett SM, Abdalla H, Carthew TL, Edstein MD. 2006. Lack of sex effect on the pharmacokinetics of primaquine. Am J Trop Med Hyg 74:951–952.
    1. Constantino L, Paixão P, Moreira R, Portela MJ, Do Rosario VE, Iley J. 1999. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in oxidative deamination of primaquine to carboxyprimaquine. Exp Toxicol Pathol 51:299–303. doi:10.1016/S0940-2993(99)80010-4.
    1. Pybus BS, Sousa JC, Jin X, Christian RE, Barnhart R, Vuong C, Sciotti RJ, Reichard GA, Kozar MP, Walker LA, Ohrt C, Melendez V. 2012. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J 11:259. doi:10.1186/1475-2875-11-259.
    1. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V. 2013. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 12:212. doi:10.1186/1475-2875-12-212.
    1. Jin X, Pybus BS, Marcsisin SR, Logan T, Luong TL, Sousa J, Matlock N, Collazo V, Asher C, Carroll D, Olmeda R, Walker LA, Kozar MP, Melendez V. 2014. An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Eur J Drug Metab Pharmacokinet 39:139−146. doi:10.1007/s13318-013-0139-8.
    1. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF. 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369:1381–1382. doi:10.1056/NEJMc1301936.
    1. Vale N, Moreira R, Gomes P. 2009. Primaquine revisited six decades after its discovery. Eur J Med Chem 44:937–953. doi:10.1016/j.ejmech.2008.08.011.
    1. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P. 2000. Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet 39:255–270. doi:10.2165/00003088-200039040-00002.
    1. Li XQ, Björkman AE, Andersson TB, Gustafsson L, Collen AE, Masimirembwa C. 2003. Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442. doi:10.1007/s00228-003-0636-9.
    1. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G. 2002. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 30:1005–1012. doi:10.1124/dmd.30.9.1005.
    1. Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, Wilairatana P, Wernsdorfer WH. 1996. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg 54:205–209.
    1. Ringwald P, Bickii J, Basco LK. 1996. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 347:24–28. doi:10.1016/S0140-6736(96)91558-5.
    1. Ringwald P, Bickii J, Basco LK. 1998. Efficacy of oral pyronaridine for the treatment of acute uncomplicated Plasmodium falciparum malaria in African children. Clin Infect Dis 26:946–953. doi:10.1086/513942.
    1. Ringwald P, Eboumbou ECM, Bickii J, Basco LK. 1999. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrob Agents Chemother 43:1525–1527.
    1. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, Borghini-Furhrer I, Rim HJ. 2012. Review of pyronaridine anti-malarial properties and product characteristics. Malar J 11:270. doi:10.1186/1475-2875-11-270.
    1. National Institute of Allergy and Infectious Diseases. 2009. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2009. Version 1.0, December 2004; clarification August 2009. .
    1. Morris CA, Lopez-Lazaro L, Jung D, Methaneethorn J, Duparc S, Borghini-Fuhrer I, Pokorny R, Shin CS, Fleckenstein L. 2012. Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers. Am J Trop Med Hyg 86:489–495. doi:10.4269/ajtmh.2012.11-0558.
    1. Navaratnam V, Ramanathan S, Wahab MS, Siew Hua G, Mansor SM, Kiechel JR, Vaillant M, Taylor WR, Olliaro P. 2009. Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur J Clin Pharmacol 65:809–821. doi:10.1007/s00228-009-0656-1.
    1. World Health Organization. 2011. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. World Health Organization; Geneva, Switzerland.
    1. Committee for Medicinal Products for Human Use. 2012. Assessment report; Pyramax. EMA/CHMP/61768/2012. Procedure no. EMEA/H/W/002319. European Medicines Agency, London, United Kingdom.
    1. Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ, Tarning J. 2014. Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN). Antimicrob Agents Chemother 58:3889–3894. doi:10.1128/AAC.02362-14.
    1. Hanpithakpong W, Kamanikom B, Dondorp AM, Singhasivanon P, White NJ, Day NP, Lindegardh N. 2008. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 876:61–68. doi:10.1016/j.jchromb.2008.10.018.
    1. Center for Drug Evaluation and Research. 2003. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations. U.S. Food and Drug Administration, Washington, DC.
    1. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. 2011. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J 10:253. doi:10.1186/1475-2875-10-253.
    1. Mihaly G, Ward S, Edwards G, Nicholl D, Orme M, Breckenridge A. 1985. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol 19:745–750.
    1. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, Hanpithakpong W, Hanboonkunupakarn B, Day NP, Ashley EA, White NJ. 2014. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother 58:3354–3359. doi:10.1128/AAC.02794-13.
    1. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, Chotsiri P, Wattanakul T, Panapipat S, Lee SJ, Day NP, White NJ. 29 September 2014. An open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult Thai subjects. Antimicrob Agents Chemother doi:10.1128/AAC.03704-14.
    1. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 46:301–306.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera